AIMS: To update the 2-year outcomes of the TOMS™ transobturator male sling for treating post-prostatectomy urinary incontinence (pRP-UI) in a group of patients previously evaluated at 1 year.
METHODS: We prospectively followed 40 patients with pRP-UI before and 6, 12, and 24 months after implantation of the TOMS™ transobturator male sling. Urinary symptoms were evaluated using the following questionnaires: USP, ICIQ, UCLA-PCI (urinary bother domain), PGI-I, and daily pad use. Success was defined as patients wearing no or only one security pad. We also report on any other surgical procedures for treating persistent incontinence during the follow-up period.
RESULTS: Of 40 patients included in the 1-year follow-up, seven required additional surgical treatment. In the remaining patients (n = 33), significant improvement (P < 0.001) compared to baseline was seen, and a subsequent tendency (non-significant) toward impairment was noted throughout the three postoperative follow-ups for the ICIQ (14.4 ± 4.4 (baseline), 7.6 ± 5.7 (6 months), 8.1 ± 5.6 (12 months), 8.9 ± 5.5 (24 months), USP-stress urinary (6.7 ± 2.2, 2.8 ± 2.4, 2.8 ± 2.4, 3.2 ± 2.8), ULCA-PCI-urinary bother (10.0 ± 12.5, 66.0 ± 33.0, 64.0 ± 31.5, 62.0 ± 30.7) scores, and pad use (2.5 ± 1.2, 0.7 ± 1.1, 0.8 ± 1.2, 0.9 ± 1.2). Significant impairment in postoperative PGI-I (6.2 ± 0.9, 6.1 ± 0.9, 5.8 ± 1.1, P = 0.028) and USP-overactive bladder symptoms scores (5.4 ± 3.6 (6 months) vs. 6.6 ± 3.7 (24 months), P = 0.046) were noted. A total of 18 (54.5%), 17 (51.5%), and 15 (45.5%) patients wore no postoperative pad, respectively.
CONCLUSION: Approximately half of the patients continue to wear no pad 2 years after TOMS™ transobturator male sling implantation. However, a tendency toward impaired continence, possibly associated with overactive bladder symptoms, was noted.
Written by:
Yiou R, Bütow Z, Parisot J, Lingombet O, Augustin D, de la Taille A, Salomon L, Audureau E. Are you the author?
Assistance Publique des Hôpitaux de Paris, Henri Mondor Teaching Hospital-Urology Department and CRCDC, Créteil, France.
Reference: Neurourol Urodyn. 2014 Oct 12. Epub ahead of print.
doi: 10.1002/nau.22668
PubMed Abstract
PMID: 25307701